SCHEMBL221697

SCHEMBL221697

CCCCCC1CCC(c2ccc(-c3ccc(C(=O)O)cc3)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.57
ALDH1A1 P00352 2/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 1/20 0.54
RARB P10826 11/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RARA P10276 1/20 0.50
MTOR P42345 1/20 0.50
MAPK1 P28482 1/20 0.48
P2RY14 Q15391 1/20 0.43
PTPN11 Q06124 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221696 1.00 CYP2C9 (0.57) CYP2C9ALDH1A1MAPTLMNARARB
Hydrochloric Acid SCHEMBL10971557 0.99 CYP2C9 (0.56) CYP2C9ALDH1A1MAPTLMNARARB
Hydrochloric Acid SCHEMBL10971561 0.99 CYP2C9 (0.56) CYP2C9ALDH1A1MAPTLMNARARB
SCHEMBL26364932 0.96 CYP2C9 (0.53) CYP2C9ALDH1A1MAPTLMNARARB
SCHEMBL17173620 0.96 CYP2C9 (0.58) CYP2C9ALDH1A1MAPTLMNARARB
SCHEMBL220859 0.96 CYP2C9 (0.61) CYP2C9ALDH1A1MAPTLMNARARB
SCHEMBL220860 0.96 CYP2C9 (0.61) CYP2C9ALDH1A1MAPTLMNARARB
SCHEMBL2492365 0.94 CYP2C9 (0.59) CYP2C9ALDH1A1MAPTLMNARARB
SCHEMBL9352218 0.94 CYP2C9 (0.59) CYP2C9ALDH1A1MAPTLMNARARB
Hydrochloric Acid SCHEMBL8556826 0.94 CYP2C9 (0.59) CYP2C9ALDH1A1MAPTLMNARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234402-B2 Mesogen compounds TRANSITIONS OPTICAL, LTD. (IE) 2025-02-25 US disclosed
CN-113122269-B Ultraviolet light absorber 光学转变公司 2024-05-28 CN disclosed
US-20230383187-A1 Mesogen Compounds TRANSITIONS OPTICAL, LTD. (IE) 2023-11-30 US disclosed
US-20230383187-A1 Mesogen Compounds TRANSITIONS OPTICAL, LTD. (IE) 2023-11-30 US disclosed
US-11781070-B2 Mesogen compounds TRANSITIONS OPTICAL, LTD. (IE) 2023-10-10 US disclosed
US-11773326-B2 Mesogen compounds TRANSITIONS OPTICAL, LTD. (IE) 2023-10-03 US disclosed
US-11773326-B2 Mesogen compounds TRANSITIONS OPTICAL, LTD. (IE) 2023-10-03 US disclosed
EP-3894514-B1 MESOGEN COMPOUNDS TRANSITIONS OPTICAL LTD (IE) 2022-11-23 EP disclosed
US-20220049161-A1 Mesogen Compounds TRANSITIONS OPTICAL, LTD. (IE) 2022-02-17 US disclosed
EP-3894514-A1 MESOGEN COMPOUNDS Transitions Optical, Ltd. (IE) 2021-10-20 EP disclosed
US-20110129678-A1 Photochromic compounds and compositions TRANSITIONS OPTICAL, INC. (US) 2011-06-02 US disclosed
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS SONY CORPORATION (JP) 2009-07-09 US disclosed
EP-1907347-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS Arcadia Pharmaceuticals Inc. (US) 2008-04-09 EP disclosed
WO-2007009083-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2007-01-18 WO disclosed
WO-2005095544-A1 LIQUID CRYSTAL COMPOUNDS, LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2005-10-13 WO disclosed
EP-0341713-A2 Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions HITACHI, LTD. (JP) 1989-11-15 EP disclosed
US-4708441-A LIQUID CRYSTALS HOFFMAN-LA ROCHE INC. (US) 1987-11-24 US disclosed
US-4652089-A PACKING FOR CHROMATOGRAPHY COLUMNS, ELECTRO-OPTICAL CELLS HOFFMANN-LA ROCHE INC. (US) 1987-03-24 US disclosed
US-4550981-A Liquid crystalline esters and mixtures HOFFMANN-LA ROCHE INC. (US) 1985-11-05 US disclosed
US-4526704-A Esters containing phenylene and cyclohexylene rings HOFFMANN-LA ROCHE INC. (US) 1985-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11781070-B2 Mesogen compounds MDN1, LSG1, MNS1 CYP2C9 4105/4885ALDH1A1 1337/4885MAPT 1511/4885
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS RARB, RARA, RARG CYP2C9 4095/4885ALDH1A1 335/4885MAPT 810/4885
US-20110129678-A1 Photochromic compounds and compositions CRY2, CRY1, PPOX CYP2C9 167/4885ALDH1A1 1243/4885MAPT 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.